Skip to content

US · STE · MEDICAL - SPECIALTIES

STERIS plc (STE) intrinsic value and stock valuation

$255.76as of 2026-11-21 · Mkt cap 22.68B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

STERIS plc DCF and intrinsic value

InvestorsCraft values STE with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from STE’s statements →

STERIS plc Graham Number

Graham Number: $114.82d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Specialties Dublin, DU 44060 steris.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$5.94B+13.8% 5y CAGRd
20122026
Net income
$785.1M+14.6% 5y CAGRd
20122026
Free cash flow
$972.4M+16.6% 5y CAGRd
20122026
Total equity
$7.2B+13.1% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$5.94B$5.46B$5.14B$4.54B$4.22B
Operating income$1.1B$866.6M$836.1M$791.1M$477.8M
Net income$785.1M$614.6M$378.2M$107M$243.9M
EPSd$7.95M$6.2M$3.81M$1.07M$2.48M
Operating cash flow$1.34B$1.15B$973.3M$757M$684.8M
Capital expenditure-$-369M-$-370.09M-$-360.33M-$-361.97M-$-287.56M
Free cash flow$972.4M$778M$613M$395M$397.3M
Total assets$10.7B$10.1B$11.1B$10.8B$11.4B
Total debt$2.09B$2.2B$3.38B$3.25B$3.28B
Net debt$1.65B$2.03B$3.18B$3.04B$2.93B
Total equity$7.2B$6.62B$6.32B$6.09B$6.54B
Cash and short-term investments$439.6M$171.7M$207M$208.4M$348.3M
Income statement
20262025202420232022
Revenue$5.94B$5.46B$5.14B$4.54B$4.22B
Cost of revenue$3.31B$3.06B$2.92B$2.56B$2.34B
Gross profit$2.63B$2.4B$2.22B$1.98B$1.88B
Research and development expenses$112.9M$107.7M$103.7M$98.5M$86.7M
Selling, general and administrative expenses$1.41B$1.33B$1.25B$1.09B$1.32B
Other expenses$4.1M$94.2M$26.1M$480K$50K
Operating expenses$1.52B$1.54B$1.38B$1.19B$1.41B
Cost and expenses$4.83B$4.59B$4.3B$3.75B$3.75B
Interest income$9.8M$8.4M$11M$0.00$6.28M
Interest expense$60.7M$86.3M$144.4M$110.8M$89.5M
Depreciation and amortization$486.5M$476.2M$565.2M$422.5M$553.1M
Ebitda$1.59B$1.36B$1.41B$1.23B$1.01B
Operating income$1.1B$866.6M$836.1M$791.1M$477.8M
Total other income/expenses, net-$-54.5M-$-70.43M-$-133.31M-$-110.83M-$-111.01M
Income before tax$1.05B$796.2M$702.8M$680.3M$366.8M
Income tax expense$262.2M$184.7M$149.5M$124.1M$82.3M
Net income$785.1M$614.6M$378.2M$107M$243.9M
Weighted average shares outstanding$98.2M$98.6M$98.8M$99.7M$97.5M
Weighted average diluted shares outstanding$98.7M$99.1M$99.4M$100.3M$98.3M
Balance sheet
20262025202420232022
Cash and short-term investments$439.6M$171.7M$207M$208.4M$348.3M
Net receivables$1.09B$1.04B$1.01B$865M$799M
Inventory$631.8M$581.3M$674.5M$604.4M$575M
Total current assets$2.39B$2B$2.87B$2.01B$1.88B
Property, plant and equipment, net$2.32B$2.11B$1.94B$1.8B$1.74B
Goodwill and intangible assets$5.81B$5.95B$6.19B$5.96B$7.73B
Long-term investments$0.00$14.3M$0.00$0.00$8.13M
Total non-current assets$8.34B$8.15B$8.19B$8.81B$9.54B
Total assets$10.7B$10.1B$11.1B$10.8B$11.4B
Accounts payable$338.8M$280.8M$251.7M$264.2M$225.7M
Short-term debt$154.7M$159.2M$117.2M$90.1M$179.4M
Deferred revenue$59.1M$57.5M$70.5M$85.7M$110.8M
Total current liabilities$1.15B$1.02B$931.1M$861.8M$922.2M
Long-term debt$1.93B$2.04B$3.27B$3.16B$3.1B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.39B$2.51B$3.82B$3.87B$3.96B
Capital lease obligations$119.6M$158.8M$177.1M$169.6M$191.5M
Total liabilities$3.54B$3.53B$4.75B$4.73B$4.88B
Common stock$0.00$4.42B$4.54B$4.49B$4.74B
Retained earnings$3.02B$2.48B$2.09B$1.91B$2B
Accumulated other comprehensive income (loss)-$-113.1M-$-292.34M-$-328.66M-$-320.71M-$-209.81M
Total equity$7.2B$6.62B$6.32B$6.09B$6.54B
Total investments$0.00$14.3M$0.00$0.00$8.13M
Total debt$2.09B$2.2B$3.38B$3.25B$3.28B
Net debt$1.65B$2.03B$3.18B$3.04B$2.93B
Cash flow statement
20262025202420232022
Net income$785.1M$616.1M$380.1M$105.8M$242.9M
Depreciation and amortization$486.5M$476.2M$565.2M$552.9M$553.1M
Stock-based compensation$61.7M$57.4M$56.5M$39M$57.7M
Change in working capital$27.2M$66.5M-$-146.08M-$-250.02M-$-149.28M
Accounts receivable-$-25.1M-$-28.82M-$-128.07M-$-133.3M-$-51.97M
Inventory-$-24M$73.1M-$-37.45M-$-123.92M-$-102.92M
Accounts payable$51.1M$33.6M-$-18.96M$53.3M$14.9M
Net cash provided by operating activities$1.34B$1.15B$973.3M$757M$684.8M
Investments in property, plant and equipment-$-369M-$-370.09M-$-360.33M-$-361.97M-$-287.56M
Acquisitions, net-$-20.1M$760.4M-$-536.8M-$-35.95M-$-380.74M
Net cash used for investing activities-$-512.5M$388.8M-$-887.36M-$-383.33M-$-666.56M
Common stock issued$32.9M$0.00$0.00$0.00$0.00
Common stock repurchased-$-235.5M-$-211.32M-$-11.77M-$-308.56M-$-55.78M
Dividends paid-$-241.8M-$-219.88M-$-200.57M-$-183.5M-$-163.17M
Net cash used for financing activities-$-568.2M-$-1.57B-$-85.19M-$-498.72M$115.8M
Net change in cash$267.9M-$-35.32M-$-1.34M-$-139.96M$127.8M
Cash at end of period$439.6M$171.7M$207M$208.4M$348.3M
Operating cash flow$1.34B$1.15B$973.3M$757M$684.8M
Capital expenditure-$-369M-$-370.09M-$-360.33M-$-361.97M-$-287.56M
Free cash flow$972.4M$778M$613M$395M$397.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About STERIS plc

        STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

        CEO
        Daniel A. Carestio
        Employees
        17.94K
        Beta
        0.92

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of STERIS plc (STE)?

        STERIS plc (STE) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is STE undervalued?

        STE trades at a price of $255.76 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.